Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of High Dose Salbutamol on Muscle Performance

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Bispebjerg Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT01415596
First received: August 11, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted

August 11, 2011
August 11, 2011
August 2011
August 2012   (final data collection date for primary outcome measure)
Muscle power
Same as current
No Changes Posted
Muscle recovery
Same as current
Not Provided
Not Provided
 
The Effect of High Dose Salbutamol on Muscle Performance
The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males

Many athletes use beta2-agonists as treatment of airway hyperresponsiveness during exercise. High dose beta2-agonists may have an ergogenic effect on exercise performance. We hypotheis that the beta2-agonist, salbutamol, taken in high doses can improve muscle power and recovery during exercise in well-trained athletes.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Ergogenic Effects of Salbutamol in Healthy Males
  • Drug: salbutamol
  • Drug: Placebo
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Active Comparator: Salbutamol
    Intervention: Drug: salbutamol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
August 2013
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males
  • age 18-45
  • training frequency > 10 hrs/wk
  • informed consent

Exclusion Criteria:

  • smoker or former smoker
  • chronic diseases, as well as asthma
  • allergy to the study drugs
  • intake of any form of medicin or inhibited drugs during the study
  • use of beta2-agonist 14 days before the intervention
Male
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01415596
SALMUS2011
Yes
Vibeke Backer, Bispebjerg Hospital
Bispebjerg Hospital
University of Copenhagen
Not Provided
Bispebjerg Hospital
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP